Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Sequential Cohort, Open-Label, Dose-Escalation Study of the Safety and CNS Exposure of Pritumumab in Patients with Brain Cancer

NCT04396717 is registered in ClinicalTrials.gov with Nascent Biotech as lead sponsor.

NCT NCT04396717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04396717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Sequential Cohort, Open-Label, Dose-Escalation Study of the Safety and CNS Exposure of Pritumumab in Patients with Brain Cancer
Lead sponsor
Nascent Biotech
Phase
Phase 1
Overall status
Completed
Start date
February 22, 2021
Completion date
January 6, 2023
Enrollment
15 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, adult, malignant primary brain tumors